Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes.
Domenico MattoscioElisa IsopiAlessia LamolinaraSara PatrunoAlessandro MeddaFederica De CeccoSusanna ChioccaManuela IezziMario RomanoAntonio RecchiutiPublished in: Journal of experimental & clinical cancer research : CR (2021)
RvD1 reduces cancer growth by activating PMN anti-cancer activities and encouraging a protective PMN-dependent recruitment of anti-tumor monocytes. These findings demonstrate efficacy of RvD1 as an innovative therapeutic able to stimulate PMN reprogramming to an anti-cancer phenotype that restrains tumor growth.